23andMe is a company.
23andMe is a company.
23andMe has raised $548.0M across 7 funding rounds.
Key people at 23andMe.
23andMe was founded by Anne Wojcicki (co-founder).
23andMe has raised $548.0M in total across 7 funding rounds.
23andMe is a genomics and biotechnology company that provides direct-to-consumer genetic testing services, enabling individuals to access, understand, and benefit from their genetic information. Its core products include the Ancestry Service, which traces family history and connects relatives, and the Health + Ancestry Service, offering insights into genetic health risks, carrier status, wellness traits, and ancestry—all delivered via saliva kits priced from $99 to $199 with results in 3-5 weeks.[1][2][6] The company serves consumers seeking personalized health, ancestry, and trait information, solving the problem of inaccessible genetic data by bypassing traditional medical gatekeepers and empowering proactive decisions on prevention and well-being.[1][4][6] Originally a high-growth pioneer, 23andMe faced setbacks leading to bankruptcy filing in March 2025, amid regulatory hurdles, data privacy issues, and market challenges, though its vast database (over 2 million genotyped customers) continues to fuel research partnerships.[2][7]
23andMe was founded on April 24, 2006, in Mountain View (later Sunnyvale), California, by Anne Wojcicki, Linda Avey, and Paul Cusenza. Wojcicki, after a decade investing in healthcare on Wall Street, grew frustrated with a system profiting from illness rather than prevention; Avey and Cusenza brought biotech expertise from Perlegen Sciences.[1][2][4][5] The idea emerged post-2003 human genome sequencing, aiming to democratize genetics via consumer kits—launching in 2007 at $999 for disease risks, ancestry, and traits.[2][4]
Early traction included Series A ($9M, 2007) and Series B ($50M, 2009) funding, price drops to $99 by 2012, and FDA clearance in 2015 after a 2013 halt, enabling clinically valid health reports.[1][2] Pivotal moments: collaborations with pharma like GSK (2015 onward) leveraging its database, and hitting research scale with millions of users, though later marred by a 2023 data breach and 2025 bankruptcy.[2][6][7]
23andMe rode the post-genome sequencing wave, pioneering consumer genomics amid Silicon Valley's 2000s startup boom (near Twitter, YouTube), making DNA testing mainstream and shifting healthcare toward prevention over treatment.[2][4][6] Timing aligned with falling sequencing costs and rising personalization trends, amplified by its database for AI-driven research and pharma alliances, influencing drug development and ecosystem-wide data sharing.[6][7] Market forces like regulatory evolution (FDA approvals) and consumer demand for ancestry/health insights favored it initially, but privacy breaches, competition (e.g., Ancestry.com), and biotech funding droughts contributed to its decline—yet its data legacy shapes precision medicine and consumer biotech.[2][6]
Post-2025 bankruptcy, 23andMe's path hinges on restructuring its ~$500M debt, monetizing its irreplaceable database via research/pharma deals, and navigating privacy regs amid AI-genomics integration. Trends like personalized medicine, CRISPR therapeutics, and consumer health tech will shape it—potentially as a data licensor or acquirer's asset, evolving from kit pioneer to research powerhouse. This echoes its founding audacity: from $999 kits to genome democratization, its legacy endures in empowering genetic access despite turbulence.[2][4][7]
23andMe was founded by Anne Wojcicki (co-founder).
23andMe has raised $548.0M in total across 7 funding rounds.
23andMe's investors include DFJ, Insight Partners, London Venture Partners, SciFi VC, Sequoia Capital, David Lau-Kee, Paul Heydon, B Capital Group, Craft Ventures, Felicis Ventures, Flybridge Capital Partners, Founders Fund.
Key people at 23andMe.
23andMe has raised $548.0M across 7 funding rounds. Most recently, it raised $83.0M Series F in December 2020.
